Atika Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Atika Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-40,000	Closed	-$2.89M	–	97
2018 Q1	$2.89M	Sell	40,000 -16,000	-29%	-$1.17M	0.99%	42
2017 Q4	$3.69M	Buy	56,000 +42,300	+309%	+$2.28M	1.43%	33
2017 Q3	$686K	Buy	+13,700	New	+$661K	0.2%	77
2015 Q3	–	Sell	-8,000	Closed	-$654K	–	70
2015 Q2	$654K	Sell	8,000 -19,500	-71%	-$1.91M	0.29%	65
2015 Q1	$2.55M	Buy	+27,500	New	+$1.77M	1.7%	27

Other funds holding ESPR

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Pentwater Capital Management Naples, Florida $14.1B AUM 58.13% 1-Year Est. Return

PFM Health Sciences San Francisco, California $950M AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return